> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bumpus Named Chief Scientific Officer at Charles River Labs
- URL: https://www.fdaweb.com/bumpus-named-chief-scientific-officer-at-charles-river-labs/
- Published: 2026-01-14T12:00:00.000Z
- Updated: 2026-09-14T15:30:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160491

Charles River Laboratories has named former FDA principal deputy commissioner **Namandjé N. Bumpus** as senior vice president and chief scientific and innovation officer. In this role, Bumpus will lead the company’s scientific strategy, oversee research and development initiatives, and advance innovation to support clients in accelerating the drug development process.

Last October, Bumpus was chosen by Charles River to chair a new global scientific advisory board to guide the company’s strategy in advancing “new approach methodologies,” non-clinical tools designed to improve the predictability of safety and efficacy while reducing reliance on animal testing.

Bumpus left FDA shortly before president Trump took office in January. She was named principal deputy commissioner in 2024, succeeding **Janet Woodcock** after her retirement. She was named chief scientist 6/2022 after serving as E.K. Marshall and Thomas H. Maren Professor and chair of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine. Previously, Bumpus was associate dean for basic research at the same school. “Bumpus’ research has focused on drug metabolism, pharmacogenetics, bioanalytical chemistry, and infectious disease pharmacology,” according to her bio.